Active substance
Results for the substance ceftazidime+avibactam
1 result
About this active substance
The combination of ceftazidime and avibactam is an antibiotic used to treat severe bacterial infections, particularly those caused by bacteria resistant to other antibiotics. Ceftazidime is a third-generation cephalosporin that works by inhibiting bacterial cell wall synthesis, leading to bacterial death. Avibactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation by beta-lactamases, including some extended-spectrum beta-lactamases (ESBLs) and carbapenemases.
This combination is indicated for the treatment of complicated infections, such as:
- Complicated intra-abdominal infections (in combination with metronidazole).
- Complicated urinary tract infections, including pyelonephritis.
- Nosocomial pneumonia, including ventilator-associated pneumonia.
- Infections caused by resistant Gram-negative bacteria, such as Klebsiella pneumoniae or Pseudomonas aeruginosa.
Common side effects include nausea, diarrhea, headache, injection site reactions, and skin rashes. Rarely, severe allergic reactions such as anaphylaxis or liver dysfunction may occur. Renal function should be monitored, as the dose needs to be adjusted in patients with renal impairment.
Ceftazidime + avibactam is administered intravenously under medical supervision, and the duration of treatment depends on the type and severity of the infection. The use of this antibiotic should be reserved for cases where other therapeutic options are not suitable, to prevent the development of bacterial resistance.
This combination is indicated for the treatment of complicated infections, such as:
- Complicated intra-abdominal infections (in combination with metronidazole).
- Complicated urinary tract infections, including pyelonephritis.
- Nosocomial pneumonia, including ventilator-associated pneumonia.
- Infections caused by resistant Gram-negative bacteria, such as Klebsiella pneumoniae or Pseudomonas aeruginosa.
Common side effects include nausea, diarrhea, headache, injection site reactions, and skin rashes. Rarely, severe allergic reactions such as anaphylaxis or liver dysfunction may occur. Renal function should be monitored, as the dose needs to be adjusted in patients with renal impairment.
Ceftazidime + avibactam is administered intravenously under medical supervision, and the duration of treatment depends on the type and severity of the infection. The use of this antibiotic should be reserved for cases where other therapeutic options are not suitable, to prevent the development of bacterial resistance.